

**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab)  
Recombinant Antibody  
Catalog # APR10399****Specification**

---

**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) - Product Information**

|                   |                            |
|-------------------|----------------------------|
| Application       | FC, Kinetics, Animal Model |
| Primary Accession | <a href="#">Q9NP84</a>     |
| Reactivity        | Human                      |
| Clonality         | Monoclonal                 |
| Isotype           | IgG1                       |
| Calculated MW     | 150 KDa                    |

**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) - Additional Information****Target/Specificity**

TNFRSF12A / TWEAKR / CD266

**Endotoxin**

&lt; 0.001EU/ µg,determined by LAL method.

**Conjugation**

Unconjugated

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) - Protein Information****Name** TNFRSF12A**Synonyms** FN14**Function**

Receptor for TNFSF12/TWEAK. Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins.

**Cellular Location**

Membrane; Single-pass type I membrane protein.


**Tissue Location**

Highly expressed in heart, placenta and kidney. Intermediate expression in lung, skeletal muscle and pancreas


**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) - Images**

Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab) is more than 98.7%, determined by SEC-HPLC.